<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969409</url>
  </required_header>
  <id_info>
    <org_study_id>HL119960</org_study_id>
    <nct_id>NCT01969409</nct_id>
  </id_info>
  <brief_title>Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>ART-IPF</acronym>
  <official_title>Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis (ART-IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent research studies have suggested that proteins called antibodies that are produced by&#xD;
      the immune system might be involved in the lung damage of idiopathic pulmonary fibrosis&#xD;
      (IPF). Antibodies produced by the immune system normal help to fight infections by attacking&#xD;
      bacteria and viruses without harming our own tissues. In patients with IPF, there is evidence&#xD;
      that certain antibodies (called autoantibodies) attack the lung and contributes to the injury&#xD;
      and scarring that occurs in IPF. Our recent studies have found that many IPF patients appear&#xD;
      to have excessive autoantibody levels in blood and lungs that might make their disease worse.&#xD;
&#xD;
      Rituximab is a medication approved by the Food and Drug Administration (FDA) for the&#xD;
      treatment of autoantibody diseases such as rheumatoid arthritis. Rituximab works by&#xD;
      destroying B cells, a type of white blood cell, called a B-lymphocyte, which produce&#xD;
      autoantibodies. In this research study, rituximab will be given into a vein to reduce the&#xD;
      autoantibody levels that we believe might be contributing to the lung damage in IPF.&#xD;
&#xD;
      This study is being conducted to determine if rituximab provides beneficial effects for IPF&#xD;
      patients by decreasing further lung injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blinded, Phase II trial in which 58 ambulatory IPF patients at any of four&#xD;
      medical centers (University of Pittsburgh, University of Chicago, Geisinger Medical Center,&#xD;
      and Temple University) will be randomized equally to 1. placebo or 2. two doses of rituximab&#xD;
      1 gm i.v., with a 14 day interval inbetween doses.&#xD;
&#xD;
      Subjects will be followed for 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Autoantibodies to Human Epidermoid (HEp)-2 Cells</measure>
    <time_frame>baseline to 9 months</time_frame>
    <description>Titers of anti-HEp-2 autoantibodies, by indirect immunofluorescence assays (IFA) over 9 months, month 9 reported. Titers represent the highest dilution of patient plasma wherein the autoantibodies can be detected. Higher titers denote greater autoantibody concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Anti-Heat Shock Protein 70 (HSP70) Autoantibodies</measure>
    <time_frame>baseline to 9 months</time_frame>
    <description>Changes of anti-HSP70 plasma concentrations as determined by ELISA, month 9 reported. The result is expressed as optical density (OD) units. The greater the number; the more autoantibody.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Forced Vital Capacity (FVC)</measure>
    <time_frame>baseline thru 9 months</time_frame>
    <description>FVC values over the observation period will be measured by spirometry, month 9 reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AE)</measure>
    <time_frame>during the 9 months of observation</time_frame>
    <description>AE in the two treatment arms will be compared. Serious adverse events, as defined by national toxicity scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Acute Exacerbations</measure>
    <time_frame>during the study duration of 9 months</time_frame>
    <description>The number of acute exacerbations, defined using consensus criteria (new/worsened hypoxemia and dyspnea, with characteristic radiographic changes within the last 30 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Survival Percentage</measure>
    <time_frame>during 9 months of observation</time_frame>
    <description>Absolute survival in the two arms calculated by actuarial methods (Kaplan-Meier). These result in percent survival denoted as means and +/- standard error (these are detailed in the outcome table below).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-Free Survival</measure>
    <time_frame>during 9 months of observation</time_frame>
    <description>Actuarial transplant-free survival in the two arms, calculated by actuarial methods (Kaplan-Meier).&#xD;
These result in percent survival denoted as means and +/- standard error (these are detailed in the outcome table below).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>during 9 months of observation</time_frame>
    <description>The number of hospitalizations in the two arms will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Ambulatory IPF</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab i.v. given on two occasions, with 14 days between doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>i.v. rituximab given on two occasions 14 days apart.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (D5W) i.v.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Ambulatory patients with a diagnosis of IPF, not established &gt;5 years from the enrollment&#xD;
        date, that fulfills American Thoracic Society (ATS)/European Thoracic Society (ETS)&#xD;
        Consensus Criteria.&#xD;
&#xD;
        Ability and willingness to give informed consent. Presence of autoantibodies against&#xD;
        Hepatoma-2 (HEp-2) cells, the assay for the primary endpoint.&#xD;
&#xD;
        Age 50-85 y.o.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Diagnoses of current infection, proven or suspected by participating physicians based upon&#xD;
        their clinical assessments.&#xD;
&#xD;
        Presence of active hepatitis B or C, or HIV infection. Presence of positive CONVENTIONAL&#xD;
        autoimmune serologic tests, e.g., Antinuclear Antibodies (ANA), Rheumatoid Factor (RF),&#xD;
        Anti-Ro, Anti-LA, Anti-Ribonucleoprotein Antibodies (RNP), Anti-Jo-1.&#xD;
&#xD;
        History of reaction to murine-derived products or any of the trial medications, or prior&#xD;
        exposures to human-murine chimeric antibodies.&#xD;
&#xD;
        Malignancy, excluding basal or squamous cell skin cancer and low-risk prostate cancer,&#xD;
        defined as stage T1 or T2a with Prostate-Specific Antigen (PSA) less than 10 ng/dl.&#xD;
&#xD;
        Unwillingness to complete post-treatment surveillance for 9 months. Diagnosis of major&#xD;
        morbidities (aside from IPF) expected to interfere with subjects' study participation for 9&#xD;
        months.&#xD;
&#xD;
        Treatment for &gt;5 days within the preceding month with &gt;10 mg. prednisone (or equivalent&#xD;
        corticosteroid) or any treatment during the preceding month with a potent cellular&#xD;
        immunosuppressant (e.g., cyclophosphamide, methotrexate, mycophenolate, azathioprine,&#xD;
        calcineurin inhibitors, etc.).&#xD;
&#xD;
        Uncontrolled diabetes or hypertension that preclude safe treatment with methylprednisolone.&#xD;
&#xD;
        Concurrent participation in other experimental trials.&#xD;
&#xD;
        Pregnancy or unwillingness to use contraception during the duration of the study among&#xD;
        female participants with child-bearing potential.&#xD;
&#xD;
        Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) &lt;70% of&#xD;
        predicted values.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven R Duncan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnestoa</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <results_first_submitted>July 8, 2020</results_first_submitted>
  <results_first_submitted_qc>November 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2021</results_first_posted>
  <disposition_first_submitted>April 2, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 2, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 7, 2020</disposition_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Steven R. Duncan, MD</investigator_full_name>
    <investigator_title>Priniciple Investigator</investigator_title>
  </responsible_party>
  <keyword>Lung</keyword>
  <keyword>Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01969409/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
        </group>
        <group group_id="P2">
          <title>Rituximab</title>
          <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
        </group>
        <group group_id="B2">
          <title>Rituximab</title>
          <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="7"/>
                    <measurement group_id="B2" value="68" spread="7"/>
                    <measurement group_id="B3" value="69" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Autoantibodies to Human Epidermoid (HEp)-2 Cells</title>
        <description>Titers of anti-HEp-2 autoantibodies, by indirect immunofluorescence assays (IFA) over 9 months, month 9 reported. Titers represent the highest dilution of patient plasma wherein the autoantibodies can be detected. Higher titers denote greater autoantibody concentrations.</description>
        <time_frame>baseline to 9 months</time_frame>
        <population>7 not analyzed: 4 deaths, 2 transplants, 1 dropout</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Autoantibodies to Human Epidermoid (HEp)-2 Cells</title>
          <description>Titers of anti-HEp-2 autoantibodies, by indirect immunofluorescence assays (IFA) over 9 months, month 9 reported. Titers represent the highest dilution of patient plasma wherein the autoantibodies can be detected. Higher titers denote greater autoantibody concentrations.</description>
          <population>7 not analyzed: 4 deaths, 2 transplants, 1 dropout</population>
          <units>titer</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288" spread="63"/>
                    <measurement group_id="O2" value="177" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Anti-Heat Shock Protein 70 (HSP70) Autoantibodies</title>
        <description>Changes of anti-HSP70 plasma concentrations as determined by ELISA, month 9 reported. The result is expressed as optical density (OD) units. The greater the number; the more autoantibody.</description>
        <time_frame>baseline to 9 months</time_frame>
        <population>7 not analyzed: 4 deaths, 2 transplants, 1 dropout</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Anti-Heat Shock Protein 70 (HSP70) Autoantibodies</title>
          <description>Changes of anti-HSP70 plasma concentrations as determined by ELISA, month 9 reported. The result is expressed as optical density (OD) units. The greater the number; the more autoantibody.</description>
          <population>7 not analyzed: 4 deaths, 2 transplants, 1 dropout</population>
          <units>OD units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.13"/>
                    <measurement group_id="O2" value="0.83" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Forced Vital Capacity (FVC)</title>
        <description>FVC values over the observation period will be measured by spirometry, month 9 reported.</description>
        <time_frame>baseline thru 9 months</time_frame>
        <population>7 not analyzed: 4 deaths, 2 transplants, 1 dropout</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Forced Vital Capacity (FVC)</title>
          <description>FVC values over the observation period will be measured by spirometry, month 9 reported.</description>
          <population>7 not analyzed: 4 deaths, 2 transplants, 1 dropout</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.14"/>
                    <measurement group_id="O2" value="2.5" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (AE)</title>
        <description>AE in the two treatment arms will be compared. Serious adverse events, as defined by national toxicity scale.</description>
        <time_frame>during the 9 months of observation</time_frame>
        <population>Data not complete in 7 due to 4 deaths, 2 transplants, 1 dropout</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AE)</title>
          <description>AE in the two treatment arms will be compared. Serious adverse events, as defined by national toxicity scale.</description>
          <population>Data not complete in 7 due to 4 deaths, 2 transplants, 1 dropout</population>
          <units>serious adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Acute Exacerbations</title>
        <description>The number of acute exacerbations, defined using consensus criteria (new/worsened hypoxemia and dyspnea, with characteristic radiographic changes within the last 30 days).</description>
        <time_frame>during the study duration of 9 months</time_frame>
        <population>Data from 7 incomplete: 4 deaths, 2 transplants, 1 dropout</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Acute Exacerbations</title>
          <description>The number of acute exacerbations, defined using consensus criteria (new/worsened hypoxemia and dyspnea, with characteristic radiographic changes within the last 30 days).</description>
          <population>Data from 7 incomplete: 4 deaths, 2 transplants, 1 dropout</population>
          <units>acute exacerbations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Survival Percentage</title>
        <description>Absolute survival in the two arms calculated by actuarial methods (Kaplan-Meier). These result in percent survival denoted as means and +/- standard error (these are detailed in the outcome table below).</description>
        <time_frame>during 9 months of observation</time_frame>
        <population>1 dropout (censored event)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Survival Percentage</title>
          <description>Absolute survival in the two arms calculated by actuarial methods (Kaplan-Meier). These result in percent survival denoted as means and +/- standard error (these are detailed in the outcome table below).</description>
          <population>1 dropout (censored event)</population>
          <units>percent of participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" spread="5"/>
                    <measurement group_id="O2" value="93" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplant-Free Survival</title>
        <description>Actuarial transplant-free survival in the two arms, calculated by actuarial methods (Kaplan-Meier).&#xD;
These result in percent survival denoted as means and +/- standard error (these are detailed in the outcome table below).</description>
        <time_frame>during 9 months of observation</time_frame>
        <population>1 dropout</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant-Free Survival</title>
          <description>Actuarial transplant-free survival in the two arms, calculated by actuarial methods (Kaplan-Meier).&#xD;
These result in percent survival denoted as means and +/- standard error (these are detailed in the outcome table below).</description>
          <population>1 dropout</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" spread="6"/>
                    <measurement group_id="O2" value="90" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalizations</title>
        <description>The number of hospitalizations in the two arms will be compared.</description>
        <time_frame>during 9 months of observation</time_frame>
        <population>incomplete data on 1 dropout</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations</title>
          <description>The number of hospitalizations in the two arms will be compared.</description>
          <population>incomplete data on 1 dropout</population>
          <units>number of admissions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.&#xD;
Placebo: Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.</description>
        </group>
        <group group_id="E2">
          <title>Rituximab</title>
          <description>Rituximab i.v. given on two occasions, with 14 days between doses.&#xD;
Rituximab: i.v. rituximab given on two occasions 14 days apart.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarct</sub_title>
                <description>myocardial infarct</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <description>Right heart failure</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Appendicitis Colitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebral vascular accident</sub_title>
                <description>stroke</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <description>syncope</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>carotid revascularization</sub_title>
                <description>carotid artery stint</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Worsening respiratory function</sub_title>
                <description>Increased dyspnea without acute exacerbation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Acute exacerbation of idiopathic pulmonary fibrosis</sub_title>
                <description>Acute exacerbation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest tightness</sub_title>
                <description>chest tightness, Not Otherwise Specified (NOS)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>arrhythmia</sub_title>
                <description>mild, NOS</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>blood pressure elevated greater than usual</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>palpitations</sub_title>
                <description>self reported palpitations NOS</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>dry eyes</sub_title>
                <description>dry eyes, self-limited</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <description>abdominal pain self limited and NOS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>loss of appetite</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>diarrhea</description>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>nausea with or without vomiting</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <description>flushing</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <description>fever self reported</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <description>dry mouth</description>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection unspecified (mild)</sub_title>
                <description>infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <description>tooth infection self-reported</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>elevated blood sugar greater than baseline</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Backache</sub_title>
                <description>back pain, self limited</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Muscle pain</sub_title>
                <description>Muscle pain other than backache (self limited)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <description>self limited joint stiffness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>anxiety</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizzyness</sub_title>
                <description>dizziness self reported</description>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>self reported fatigue NOS</description>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>headache</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>trouble sleeping</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <description>urinary tract infection documented by culture or suspected</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <description>Cough greater than baseline</description>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Post-nasal drip</sub_title>
                <description>post-nasal discharge</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Shortness of breath greater than baseline not attributable to acute exacerbations, pneumonia, or causes other than idiopathic pulmonary fibrosis</description>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E2" events="18" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <description>pruritis</description>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>skin rash NOS</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Brusing</sub_title>
                <description>Ecchymosis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven R. Duncan, MD</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>(205) 934-5017</phone>
      <email>duncsr19@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

